Muhammad Faisal

Dr. Muhammad Faisal

Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore
+1
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MFMuhammad Faisal
Muhammad Faisal
MBMuhammad Abu Bakar
Muhammad Abu Bakar
ASAlbash Sarwar
Albash Sarwar
MAMohammad Adeel
Mohammad Adeel
FBFatima Batool
Fatima Batool
RHRaza Hussain
Raza Hussain
The new AJCC staging system (8th edition) incorporates depth of invasion to stage oral cancers. It is a recognized predictor for neck nodal metastasis and local recurrence, the associated risk is not well defined. The aim of this study was to explore the risk of occult neck nodal metastasis and local recurrence in relation to depth in early stage squamous cell carcinoma of oral tongue. We have evaluated records of 179 patients with early tongue cancer treated in our unit from 2006–2015 with a mean age of 57.92 ± 11.93 years. Treatment modalities used were surgery (26%), surgery followed by radiotherapy (64%) and chemo-radiation (10%). Neck dissection was ipsilateral in 94% and bilateral in 6% of the patients. Patients were grouped according to the AJCC cut off points in 8th edition for depth; group A: 1–5 mm (35%), group B: 6–10 mm (47%) and group C: > 10 mm (18%). Risk of local recurrence and nodal metastasis for Group A was 15% (10/63) and 23% (15/63), group B 20% (17/84) and 34% (29/84), and group C 40% (13/32) and 53% (17/32). Depth more than 10 mm is associated with significantly increased risk of recurrence and nodal metastasis. Elective neck dissection should be a consideration for tumors having depth less than 5mm.

1 July 2013 in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Verified
Journal Article
Closed access
RWRiaz Warraich
Riaz Warraich
MFMuhammad Faisal
Muhammad Faisal
MRMadiha Rana
Madiha Rana
ASAnjum Shaheen
Anjum Shaheen
NGNils-Claudius Gellrich
Nils-Claudius Gellrich
MRMajeed Rana
Majeed Rana

21 April 2020 in Head & Neck
Verified
Journal Article
Closed access
PDF file
NLNguyen-Son Le
Nguyen-Son Le
SJStefan Janik
Stefan Janik
DLDavid T. Liu
David T. Liu
SGStefan Grasl
Stefan Grasl
MFMuhammad Faisal
Muhammad Faisal
Boban M. ErovićBoban M. Erović
Boban M. Erović

1 January 2018 in Annals of Maxillofacial Surgery
Verified
Journal Article
Open access
PDF file
MFMuhammad Faisal
Muhammad Faisal
MAMohammad Adeel
Mohammad Adeel
SRSheryar Riaz
Sheryar Riaz
AAAbdullah Anwar
Abdullah Anwar
ARAsma Rashid
Asma Rashid
RHRaza Hussain
Raza Hussain
Objectives: The submental flap provides an alternative technique in orofacial reconstruction, especially in situations where free flap services are not available. The objective of this study is to demonstrate the oncological safety and benefits of this flap in oral cavity reconstruction in a tertiary care cancer hospital. Materials and Methods: A total of 27 patients with oral cavity cancers, which underwent submental flap reconstruction from 2015 to 2017 at Shaukat Khanum Cancer Memorial Hospital, were included in the study. We have retrospectively reviewed records of these patients. Results: There were 25 male and 2 female patients with age ranging from 21 to 73 years. Most common primary tumor sites were buccal mucosa (13), tongue (7), and lower alveolus (7). All patients underwent ipsilateral selective neck dissection after flap was harvested. Complete flap loss was observed in three, whereas one patient had flap dehiscence that subsequently healed. Mean follow-up was 11 months. There were four regional recurrences but no local recurrence. On the last follow-up (minimum 6 months), 15 patients were alive without any disease, 4 were alive with disease, and 3 had died. Conclusion: Submental flap is a satisfactory option for oral cavity reconstruction. However, preoperative selection of clinically neck node-negative patient is extremely important as it has potential risk of occult metastasis.

27 August 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MFMuhammad Faisal
Muhammad Faisal
SHSabrina Hartenbach
Sabrina Hartenbach
ASAnnemarie Schratter
Annemarie Schratter
WKWolfgang J. Köstler
Wolfgang J. Köstler
HKHannes Kaufmann
Hannes Kaufmann
Boban M. ErovićBoban M. Erović
Boban M. Erović
(1) Background: Lymphoepithelial carcinoma of the hypopharynx and larynx is a rare tumor with fewer than 50 cases in the published literature. We present a literature review to discuss the clinical findings, viral or genetic associations, diagnostic challenges, histopathological findings and therapeutic aspects of the disease. (2) Methods: A comprehensive literature review was performed through MEDLINE/PubMed from 1968 to 2018. We identified 21 studies comprising 46 patients. Data on all the clinicopathological features, diagnostic modalities, treatment options and viral or genetic etiology were extracted and analyzed using SPSS. (3) Results: The mean age of presentation was 64 years (range 40–82 years) and mostly involved males. The supraglottis and pyriform sinus were the most commonly involved sub-sites, with surgery as the preferred treatment modality. The presence of the Epstein–Barr virus possibly directs a viral etiology. The incidence of cervical and distant metastasis was 54% and 21%, respectively. The median survival time was 30 months. (4) Conclusions: Lymphoepithelial carcinoma of the hypopharynx is an aggressive tumor with a strong predilection for regional and distant metastasis. Surgery, in combination with adjuvant therapy, provides promising results. Immunohistochemistry helps in differentiating LEC from other pathologies.

12 March 2017 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
OWOmer Waqas
Omer Waqas
MFMuhammad Faisal
Muhammad Faisal
IHIrfan Haider
Irfan Haider
AAAwais Amjad
Awais Amjad
AJArif Jamshed
Arif Jamshed
RHRaza Hussain
Raza Hussain
Adnexal tumors of the skin are a large and diverse group of benign and malignant neoplasms, which exhibit morphological differentiation toward one of the different types of adnexal epithelium present in normal skin and they pose a diagnostic challenge. The purpose of this study is to share our experience with these rare but aggressive tumors at a tertiary care cancer hospital in a developing country. A retrospective review of 11 patients diagnosed with rare adnexal tumors and their variants from January 2005 to December 2014, treated either surgically or non-surgically, was performed to describe the clinicopathological characteristics and outcome of the disease. A total of 11 patients were diagnosed with adnexal carcinoma and its variants: a 34-year-old Sindhi man, a 59-year-old Punjabi woman, a 32-year-old woman from Khyber Pakhtunkhwa, a 43-year-old Punjabi woman, a 64-year-old Punjabi man, a 51-year-old man from Khyber Pakhtunkhwa, a 51-year-old Punjabi woman, a 74-year-old Punjabi woman, a 75-year-old Punjabi man, a 61-year-old man from Khyber Pakhtunkhwa, and a 53-year-old man from Khyber Pakhtunkhwa. The male to female ratio was 1.2:1. The histological variations were sebaceous differentiation (n = 4), microcystic adnexal carcinoma (n = 4), trichilemmal carcinoma (n = 1), pilomatrix carcinoma (n = 1), and hidradenocarcinoma (n = 1). The mean age at presentation was 54 years (range 32 to 75). The primary subsite of involvement was the scalp in nine patients followed by eyelids in two patients. Surgery was the primary treatment modality in almost all patients; postoperative radiotherapy (PORT) was offered to eight patients. The median dose of radiation was 45 Gy to the primary site. Indications for radiotherapy included close margins (n = 2), positive margins (n = 1), high grade histology (n = 4), and multifocal disease (n = 1). On follow-up, two patients presented with local, one regional and two patients developed distant metastasis. Adnexal carcinomas are rare tumors with diverse histological patterns and a tendency for locoregional and distant metastasis. Surgery should be the mainstay of treatment reserving radiotherapy for adjuvant, palliative, and re-treatment scenarios.